scholarly journals Rapid suppression of bone formation marker in response to sleep restriction and circadian disruption in men

2019 ◽  
Vol 30 (12) ◽  
pp. 2485-2493 ◽  
Author(s):  
C.M. Swanson ◽  
W.M. Kohrt ◽  
P. Wolfe ◽  
K.P. Wright ◽  
S.A. Shea ◽  
...  
Keyword(s):  
Bone Formation ◽  
Circadian Disruption ◽  
Sleep Restriction ◽  
Bone Formation Marker

scholarly journals Bone Turnover Markers After Sleep Restriction and Circadian Disruption: A Mechanism for Sleep-Related Bone Loss in Humans

2017 ◽  
Vol 102 (10) ◽  
pp. 3722-3730 ◽  
Author(s):  
Christine M Swanson ◽  
Steven A Shea ◽  
Pamela Wolfe ◽  
Sean W Cain ◽  
Mirjam Munch ◽  
...  
Keyword(s):  
Bone Resorption ◽  
Bone Formation ◽  
Bone Turnover ◽  
Repeated Measures ◽  
Circadian Disruption ◽  
Sleep Restriction ◽  
Type I ◽  
Bone Biomarkers ◽  
Mineral Density ◽  
The Impact

Abstract Context Sleep abnormalities are associated with low bone mineral density. Underlying mechanisms are unknown. Objective Investigate the impact of sleep restriction with circadian disruption on bone biomarkers. Design Intervention study. Participants and Methods Four bone biomarkers [C-terminal cross-linked telopeptide of type I collagen (CTX) = bone resorption, N-terminal propeptide of type I procollagen (P1NP) = bone formation, sclerostin and fibroblast growth factor 23 = osteocyte function] were measured in bihourly serum samples over 24 hours at baseline and after ∼3 weeks of sleep restriction (5.6 hours sleep/24 hours) with concurrent circadian disruption (recurring 28-hour “day” in dim light) in 10 men (age groups: 20 to 27 years, n = 6; 55 to 65 years, n = 4). The effects of sleep/circadian disruption and age on bone biomarker levels were evaluated using maximum likelihood estimation in a mixed model for repeated measures. Results P1NP levels were lower after intervention compared with baseline (P < 0.001); the decrease in P1NP was greater for younger compared with older men (28.0% vs 18.2%, P < 0.001). There was no change in CTX (Δ = 0.03 ± 0.02 ng/mL, P = 0.10). Sclerostin levels were higher postintervention in the younger men only (Δ = 22.9% or 5.64 ± 1.10 pmol/L, P < 0.001). Conclusions These data suggest that 3 weeks of circadian disruption with concurrent sleep restriction can lead to an uncoupling of bone turnover wherein bone formation is decreased but bone resorption is unchanged. Circadian disruption and sleep restriction may be most detrimental to bone in early adulthood.

scholarly journals Sleep Restriction With Circadian Disruption Negatively Alter Bone Turnover Markers in Women

2020 ◽  
Vol 105 (7) ◽  
pp. 2456-2463 ◽  
Author(s):  
Christine M Swanson ◽  
Steven A Shea ◽  
Wendy M Kohrt ◽  
Kenneth P Wright ◽  
Sean W Cain ◽  
...  
Keyword(s):  
Bone Resorption ◽  
Bone Formation ◽  
Bone Turnover ◽  
Young Women ◽  
Bone Turnover Markers ◽  
Circadian Disruption ◽  
Sleep Restriction ◽  
Type I ◽  
Bone Biomarkers ◽  
Turnover Markers

Abstract Purpose The purpose of this work is to determine whether an uncoupling of bone turnover markers (BTMs) occurs in women exposed to the combination of sleep restriction with circadian disruption (SRCD), as previously reported in men. Methods Four bone biomarkers (N-terminal propeptide of type I procollagen [P1NP] and osteocalcin = bone formation; C-telopeptide [CTX] = bone resorption; sclerostin = bone formation inhibitor) were measured in bihourly samples over 24 hours at baseline and after approximately 3 weeks of sleep restriction (~5.6 hours of sleep/24 hours) with concurrent circadian disruption (SRCD, recurring 28-hour “day” in dim light). Maximum likelihood estimation in a repeated-measures model was used to assess the effects of SRCD and age on bone biomarkers. Results Five women were young (22 ± 2.8 years) and four were older (58 ± 1.8 years). Baseline bone biomarker levels did not differ by age (all P ≥ .07). Bone formation markers were lower after SRCD (estimate ± SEE, ΔP1NP = –9.5 ± 2.8 μg/L, P = .01; Δosteocalcin = –2.3 ± 0.9 ng/mL, P = .04). The P1NP decline was greater in young women (ΔP1NP = –12.9 ± 3.7 μg/L, P = .01). After SRCD, CTX was significantly higher in young women (0.182 ± 0.069 ng/mL, P = .04) but did not change in older women. Conclusions These pilot data are similar to previous findings in men and suggest that SRCD negatively altered bone metabolism in women by decreasing markers of bone formation and, in young women, increasing a marker of bone resorption. If sustained, this pattern of BTM uncoupling may lead to bone loss and lower bone mineral density.

scholarly journals Serum bone formation marker correlation with improved osseointegration in osteoporotic rats treated with simvastatin

2011 ◽  
Vol 24 (4) ◽  
pp. 422-427 ◽  
Author(s):  
Zhibin Du ◽  
Jiang Chen ◽  
Fuhua Yan ◽  
Nghiem Doan ◽  
Saso Ivanovski ◽  
...  
Keyword(s):  
Bone Formation ◽  
Bone Formation Marker

Quercetin prevents experimental glucocorticoid-induced osteoporosis: a comparative study with alendronate

2013 ◽  
Vol 91 (5) ◽  
pp. 380-385 ◽  
Author(s):  
Hoda Derakhshanian ◽  
Mahmoud Djalali ◽  
Abolghassem Djazayery ◽  
Keramat Nourijelyani ◽  
Sajad Ghadbeigi ◽  
...  
Keyword(s):  
Bone Formation ◽  
Breaking Strength ◽  
Sodium Succinate ◽  
Treated Group ◽  
Common Type ◽  
Bone Formation Marker ◽  
Sprague Dawley ◽  
Oral Gavage ◽  
Methylprednisolone Sodium Succinate ◽  
Sprague Dawley Rats

Glucocorticoid-induced osteoporosis (GIO) is the most common type of secondary osteoporosis. The aim of this study was to compare the efficacy of quercetin, a plant-derived flavonoid, with alendronate in the prevention of GIO. Fifty-six Sprague–Dawley rats were randomly distributed among 7 groups (8 rats per group) and treated for 6 weeks with one of the following: (i) normal saline; (ii) 40 mg methylprednisolone sodium succinate (MP)/kg body mass; (iii) MP + 40 μg alendronate/kg; (iv) MP + 50 mg quercetin/kg; (v) MP + 40 μg alendronate/kg + 50 mg quercetin/kg; (vi) MP + 150 mg quercetin/kg; and (vii) MP + 40 μg alendronate/kg + 150 mg quercetin/kg. MP and alendronate were injected subcutaneously and quercetin was administered by oral gavage 3 days a week. At the end of the study, femur breaking strength was significantly decreased as a consequence of MP injection. This decrease was completely compensated for in groups receiving 50 mg quercetin/kg plus alendronate, and 150 mg quercetin/kg with or without alendronate. Quercetin noticeably elevated osteocalcin as a bone formation marker, while alendronate did not show such an effect. In addition, administration of 150 mg quercetin/kg increased femoral trabecular and cortical thickness by 36% and 22%, respectively, compared with the MP-treated group. These data suggest that 150 mg quercetin/kg, alone or in combination with alendronate, can completely prevent GIO through its bone formation stimulatory effect.

scholarly journals Comparison of BMD Changes and Bone Formation Marker Levels 3 Years After Bisphosphonate Discontinuation: FLEX and HORIZON‐PFT Extension I Trials

2019 ◽  
Vol 34 (5) ◽  
pp. 810-816 ◽  
Author(s):  
Tiffany Y Kim ◽  
Douglas C Bauer ◽  
Brian L McNabb ◽  
Anne L Schafer ◽  
Felicia Cosman ◽  
...  
Keyword(s):  
Bone Formation ◽  
Bone Formation Marker

scholarly journals Effect of denosumab on bone formation marker P1NP

2017 ◽  
Vol 3 (3) ◽  
pp. S34
Author(s):  
Hitoshi Tanigawa ◽  
Y. Imoto ◽  
S. Nishiwaki ◽  
Y. Tamagawa ◽  
S. Imai
Keyword(s):  
Bone Formation ◽  
Bone Formation Marker

114 Stability of Gut Microbiome Alpha Diversity During Combined Sleep Restriction and Circadian Misalignment

SLEEP ◽  
2021 ◽  
Vol 44 (Supplement_2) ◽  
pp. A46-A47
Author(s):  
Dana Withrow ◽  
Antonio Gonzalez ◽  
Kate Sprecher ◽  
Christopher Depner ◽  
Tina Burke ◽  
...  
Keyword(s):  
Gut Microbiome ◽  
Intraclass Correlation ◽  
Correlation Coefficients ◽  
Alpha Diversity ◽  
Healthy Adults ◽  
Circadian Disruption ◽  
Sleep Restriction ◽  
Circadian Misalignment ◽  
Intraclass Correlation Coefficients ◽  
Diversity Measures

Abstract Introduction Disturbed gut microbiome diversity has been associated with poor health outcomes and various disease states. We investigated the impact of combined sleep restriction (3h time in bed [TIB] sleep opportunities per day) and circadian misalignment (daytime sleep and nighttime wakefulness) on gut microbiome alpha diversity in healthy young individuals in a controlled laboratory setting. Methods Twenty healthy adults (8 female), mean age (±SD) 25.65(±4.2) completed a 39-day protocol consisting of two laboratory visits lasting 4 days each. Two weeks of ambulatory monitoring prior to laboratory visits confirmed ~8h habitual sleep duration per night. Participants consumed energy-balanced diets, identical within participants, 2 days before and during the laboratory visits. The laboratory visits consisted of sleep opportunities as follows: night 1 (8h TIB), night 2 (3h TIB), day 3 (3h TIB) and day 4 (3h TIB). Fecal microbiome samples were obtained at baseline between day 1 and 2, and during sleep and circadian disruption (between day 3 and 4). Alpha diversity measures were calculated using Pielou’s evenness, Faith’s phylogenetic diversity and number of observed OTUs. Results Linear mixed models with subject as a random factor and visit as a fixed factor were performed to assess whether any alpha diversity measures changed during sleep and circadian disruption compared to baseline. Alpha diversity did not change significantly between baseline and sleep and circadian disruption (all p > 0.57). Additionally, intraclass correlation coefficients (ICCs) were calculated at baseline and during sleep and circadian disruption to determine if alpha diversity measures showed trait-like stability at both time points. ICCs were substantial to almost perfect (ICC 0.64–0.84) at baseline and substantial (ICC 0.70–0.80) during sleep and circadian disruption. Conclusion Four days of combined sleep restriction and circadian misalignment does not appear to alter alpha diversity of gut microbiota species in healthy adults. Further, substantial to almost perfect intraclass correlation coefficients suggest alpha diversity of the human microbiome is stable during combined sleep and circadian perturbation and that examination at the level of microbiota community composition and functional outcomes are needed. Support (if any) Office of Naval Research MURI (N00014- 15-1-2809), NIH/NCATS (UL1TR002535), NIH T32 HL149646, CU Undergraduate Research Opportunities.

scholarly journals Impact of Artistic Gymnastics on Bone Formation Marker, Density and Geometry in Female Adolescents: ABCD-Growth Study

2019 ◽  
Vol 26 (2) ◽  
pp. 75 ◽  
Author(s):  
Isabella Neto Exupério ◽  
Ricardo Ribeiro Agostinete ◽  
André Oliveira Werneck ◽  
Santiago Maillane-Vanegas ◽  
Rafael Luiz-de-Marco ◽  
...  
Keyword(s):  
Bone Formation ◽  
Female Adolescents ◽  
Marker Density ◽  
Bone Formation Marker ◽  
Growth Study

scholarly journals Interleukin-6 May Not Affect Bone Resorption Marker CTX or Bone Formation Marker P1NP in Humans

2020 ◽  
Vol 4 (9) ◽  
Author(s):  
Louise L Lehrskov ◽  
Sasha Kjeldsen ◽  
Mark P Lyngbæk ◽  
Regitse Højgaard Chirstensen ◽  
Anne-Sophie Wedell-Neergaard ◽  
...  
Keyword(s):  
Bone Resorption ◽  
Bone Formation ◽  
Crossover Study ◽  
Bone Remodeling ◽  
Interleukin 6 ◽  
Plasma Concentrations ◽  
Bone Resorption Marker ◽  
Healthy Individuals ◽  
Bone Formation Marker ◽  
Double Blinded

Abstract Context Interleukin 6 (IL-6) contributes to bone remodeling in preclinical studies. Clinical trials investigating the role of IL-6 in bone remodeling are limited. Objective To investigate if IL-6 regulates bone remodeling in humans. Design Plasma concentrations of the bone resorption marker carboxy-terminal type I collagen crosslinks (CTX) and of the bone formation marker procollagen type 1 N-terminal propeptide (P1NP) were measured during a mixed-meal tolerance test (MMTT) in 3 placebo-controlled human studies. Participants Five healthy individuals participated in study 1; 52 obese individuals, in study 2; and 10 healthy individuals, in study 3. Interventions Study 1 was a single-blinded crossover study consisting of a 1-h infusion of saline (placebo) or the IL-6 receptor antibody tocilizumab followed by an exercise bout. Study 2 was a randomized, double-blinded 12-week exercise training intervention study. Participants received infusions of saline or tocilizumab. Study 3 was a randomized, double-blinded, crossover study consisting of 30 min infusion of saline or IL-6. Main outcomes measures Effect of IL-6 on CTX levels. Results CTX was significantly (P < 0.01) decreased during MMTTs in all 3 studies. Treatment with tocilizumab did not affect exercise or meal induced changes in plasma CTX or P1NP concentrations acutely (study 1) or after a 12-week treatment period (study 2). Exogenous IL-6 had no effect on CTX or P1NP plasma concentrations (study 3). Conclusions IL-6 may not regulate bone remodeling in humans.

scholarly journals Adverse Metabolic Consequences in Humans of Prolonged Sleep Restriction Combined with Circadian Disruption

2012 ◽  
Vol 4 (129) ◽  
pp. 129ra43-129ra43 ◽  
Author(s):  
O. M. Buxton ◽  
S. W. Cain ◽  
S. P. O'Connor ◽  
J. H. Porter ◽  
J. F. Duffy ◽  
...  
Keyword(s):  
Circadian Disruption ◽  
Sleep Restriction
Sign in / Sign up

Export Citation Format

Share Document